At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓ECOG performance status 0-1
- ✓Histologically confirmed gastric or gastroesophageal junction adenocarcinoma
- ✓Histologically confirmed esophageal adenocarcinoma
- ✕Prior PD-1 or PD-L1 inhibitor treatment (except HCC and gastric/esophageal cancer patients)
- ✕Prior cabozantinib or MET/HGF inhibitor treatment
- ✕Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months
- ✕Tumor invading GI tract (T4 primary tumor)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)
In Brief
A Phase 2 clinical trial evaluating Cabozantinib, Durvalumab, and 1 other intervention for Gastric Cancer and 3 related conditions. Currently recruiting, targeting 117 participants across 2 sites.
Detailed Summary
The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. The investigators believe that modulating the tumor microenvironment with biologic agents like cabozantinib will have synergistic effect when combined with checkpoint-based immunotherapeutics like durvalumab in this patient population. This is a phase I/II, open label, multi-cohort trial looking at safety, tolerability and efficacy endpoints.
Study Details
Timeline
Interventions
by mouth
infusion
infusion